Physician profile
Mark Sterling
NPI 1114949450
$1,762.49
in general payments reported to CMS, 2019-2025
15 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $102 · 2021: $356 · 2022: $174 · 2023: $422 · 2024: $275 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.02 | 2022-2025 | Botox |
| Allergan, INC. | $389.62 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $166.74 | 2023-2024 | Ztlido |
| Depuy Synthes Sales INC. | $147.55 | 2020-2025 | Orthovisc, Monovisc |
| Amgen INC. | $133.74 | 2019-2023 | Prolia, Evenity |
| Medtronic USA, INC. | $130.26 | 2019 | |
| Horizon Therapeutics Plc | $52.51 | 2021-2022 | |
| Pfizer INC. | $38.16 | 2021 | |
| Ferring Pharmaceuticals INC. | $35.66 | 2021-2023 | Euflexxa |
| Vertex Pharmaceuticals Incorporated | $34.40 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $31.37 | 2022-2023 | Seglentis |
| Bioventus LLC | $20.27 | 2024 | Durolane |
| Stryker Corporation | $18.27 | 2025 | Optablate |
| Covidien Lp | $17.53 | 2019 | |
| Zyla Life Sciences, INC. | $16.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.